Suppr超能文献

针对哮喘患者进行长期全身性皮质类固醇治疗的骨骼研究。

Bone studies in patients on prolonged systemic corticosteroid therapy for asthma.

作者信息

Greenberger P A, Hendrix R W, Patterson R, Chmiel J S

出版信息

Clin Allergy. 1982 Jul;12(4):363-8. doi: 10.1111/j.1365-2222.1982.tb02540.x.

Abstract

Cortical thickness of the second metacarpal bone and lumbar spine fractures were determined radiographically in twenty-one caucasian corticosteroid-dependent asthmatics (mean age, 61.2 years; range 47-73 years). The mean number of prednisone years per patient of continuous corticosteroid treatment averages 9.7 (range 5.0-21.5 years), and the mean accumulated dose of prednisone was 46.7 g (range 10.7-160 g). Thirteen of twenty-one (61.9%) patients had cortical thickness between 1 and 2 standard deviations (s.d.) below the age- and sex-specific mean for normals, but only four (19%) patients fell below 2 s.d. Although the study indicated decreased cortical thickness in the prednisone-treated group, in only one (4.8%) patient were vertebral fractures present, an incidence not unexpected in this group. In serious chronic asthma, concern for bone structure should not prohibit the cautious use of appropriate corticosteroid regimens at the lowest possible maintenance dose.

摘要

对21名依赖皮质类固醇的白种人哮喘患者(平均年龄61.2岁;范围47 - 73岁)进行了影像学检查,以确定第二掌骨和腰椎骨折的皮质厚度。每位患者连续皮质类固醇治疗的泼尼松使用年限平均为9.7年(范围5.0 - 21.5年),泼尼松的平均累积剂量为46.7克(范围10.7 - 160克)。21名患者中有13名(61.9%)的皮质厚度低于正常年龄和性别的平均值1至2个标准差(s.d.),但只有4名(19%)患者低于2个标准差。尽管研究表明泼尼松治疗组的皮质厚度降低,但只有1名(4.8%)患者出现椎体骨折,该组出现这种情况的发生率并不意外。在严重的慢性哮喘中,对骨骼结构的担忧不应妨碍在尽可能低的维持剂量下谨慎使用适当的皮质类固醇治疗方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验